HOUSTON , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the appointment of industry veteran and oncologist, Reshma Rangwala , M.D., Ph.D., as Chief Medical Officer. “We are honored that Dr.
HOUSTON , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following two virtual investor conferences in September: Cantor
Expands Clinical Development and Oncology Expertise as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer HOUSTON , Aug. 27, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics, today announced the
Successfully completed Phase 1b trial of AVB-500 in Platinum Resistant Ovarian Cancer with encouraging clinical data showing 60% ORR in the subpopulation that has not previously been treated with bevacizumab On-track to discuss the potential pivotal trial of AVB-500 with FDA this year On-track to
HOUSTON , July 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following three virtual investor conferences in August: William
Identifies Recommended Phase 2 Dose for Continued Clinical Development of AVB-500 in Platinum Resistant Ovarian Cancer Aravive to Host Conference Call and Webcast Today at 8:30 a.m. ET HOUSTON , July 23, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage oncology company
HOUSTON , June 30, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that the Company has been added to the Russell
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in mid-2020 HOUSTON , May 06, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the
HOUSTON and SHANGHAI , April 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced a strategic collaboration
Healthcare Entrepreneur Fred Eshelman , Pharm.D., Appointed Board Chairman Aravive’s Chief Scientific Officer, Gail McIntyre , Ph.D., Appointed CEO Aravive to Host Conference Call Today at 9:00 AM ET HOUSTON , April 09, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc.
